CACNA1A and breast cancer: Moreover, clinical trials using the SMAC mimetic BI 891065 for the targeting cIAP1, cIAP2, and XIAP in combination with the anti-PD1 antibody BI 754091 against solid tumors include the treatment of BC patients and will show whether the SMAC mimetics are helpful in the future immunotherapy of BC (NCT03166631, NCT04138823).